Literature DB >> 30888548

Cancer Explant Models.

Christian T Stackhouse1, George Yancey Gillespie2, Christopher D Willey3.   

Abstract

Overcoming the challenges of understanding and treating cancer requires reliable patient-derived models of cancer (PDMCs). For decades, cancer research and therapeutic development relied primarily on cancer cell lines because of their prevalence, reproducibility, and simplicity to maintain. However, findings from research conducted in cell lines are rarely recapitulated in vivo and seldom directly translatable to patients. The tumor microenvironment (TME), tumor-stromal interactions, and associations with host immune cells produce profound changes in tumor phenotype and complexity not captured in traditional monolayer cell culture. In this chapter, we present various cancer explant models and discuss their applicability based on specific research aims. We discuss the appropriateness of these models for basic science questions, drug screening/development, and for personalized, precision medicine. We also consider logistical factors such as resource cost, technical difficulty, and accessibility. We finish this chapter with a practical guide intended to help the reader select the cancer explant model system(s) that best address their research aims.

Entities:  

Mesh:

Year:  2021        PMID: 30888548     DOI: 10.1007/82_2019_157

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  59 in total

1.  Eye irritation of low-irritant cosmetic formulations: correlation of in vitro results with clinical data and product composition.

Authors:  Caroline Debbasch; Catherine Ebenhahn; Nadia Dami; Marc Pericoi; Christine Van den Berghe; Martine Cottin; Gerhard J Nohynek
Journal:  Food Chem Toxicol       Date:  2005-01       Impact factor: 6.023

2.  Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.

Authors:  Joshua C Anderson; Christine W Duarte; Karim Welaya; Timothy D Rohrbach; Markus Bredel; Eddy S Yang; Nirmal V Choradia; Jaideep V Thottassery; George Yancey Gillespie; James A Bonner; Christopher D Willey
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

Review 3.  In Vitro Model of the Epidermis: Connecting Protein Function to 3D Structure.

Authors:  Christopher Arnette; Jennifer L Koetsier; Paul Hoover; Spiro Getsios; Kathleen J Green
Journal:  Methods Enzymol       Date:  2015-08-20       Impact factor: 1.600

4.  Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation.

Authors:  Efraín A Cermeño; Andrés J García
Journal:  Curr Stem Cell Rep       Date:  2016-02-09

5.  Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.

Authors:  Qian Chen; Ligeng Xu; Jiawen Chen; Zhijuan Yang; Chao Liang; Yu Yang; Zhuang Liu
Journal:  Biomaterials       Date:  2017-09-23       Impact factor: 12.479

6.  Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer.

Authors:  Yoon Young Choi; Jae Eun Lee; Hyunki Kim; Moon Hee Sim; Ka-Kyung Kim; Gunho Lee; Hyoung-Il Kim; Ji Yeong An; Woo Jin Hyung; Choong-Bai Kim; Sung Hoon Noh; Sangwoo Kim; Jae-Ho Cheong
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

Review 7.  3D bioprinting: improving in vitro models of metastasis with heterogeneous tumor microenvironments.

Authors:  Jacob L Albritton; Jordan S Miller
Journal:  Dis Model Mech       Date:  2017-01-01       Impact factor: 5.758

Review 8.  Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.

Authors:  William K Decker; Rodrigo F da Silva; Mayra H Sanabria; Laura S Angelo; Fernando Guimarães; Bryan M Burt; Farrah Kheradmand; Silke Paust
Journal:  Front Immunol       Date:  2017-08-02       Impact factor: 7.561

9.  Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.

Authors:  Shumei Chia; Joo-Leng Low; Xiaoqian Zhang; Xue-Lin Kwang; Fui-Teen Chong; Ankur Sharma; Denis Bertrand; Shen Yon Toh; Hui-Sun Leong; Matan T Thangavelu; Jacqueline S G Hwang; Kok-Hing Lim; Thakshayeni Skanthakumar; Hiang-Khoon Tan; Yan Su; Siang Hui Choo; Hannes Hentze; Iain B H Tan; Alexander Lezhava; Patrick Tan; Daniel S W Tan; Giridharan Periyasamy; Judice L Y Koh; N Gopalakrishna Iyer; Ramanuj DasGupta
Journal:  Nat Commun       Date:  2017-09-05       Impact factor: 14.919

10.  MMP proteolytic activity regulates cancer invasiveness by modulating integrins.

Authors:  Alakesh Das; Melissa Monteiro; Amlan Barai; Sandeep Kumar; Shamik Sen
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

View more
  2 in total

1.  A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening.

Authors:  Christian T Stackhouse; James R Rowland; Rachael S Shevin; Raj Singh; G Yancey Gillespie; Christopher D Willey
Journal:  Cells       Date:  2019-07-11       Impact factor: 6.600

2.  An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases.

Authors:  Christian T Stackhouse; Joshua C Anderson; Zongliang Yue; Thanh Nguyen; Nicholas J Eustace; Catherine P Langford; Jelai Wang; James R Rowland; Chuan Xing; Fady M Mikhail; Xiangqin Cui; Hasan Alrefai; Ryan E Bash; Kevin J Lee; Eddy S Yang; Anita B Hjelmeland; C Ryan Miller; Jake Y Chen; G Yancey Gillespie; Christopher D Willey
Journal:  JCI Insight       Date:  2022-08-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.